We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sopheon Plc | LSE:SPE | London | Ordinary Share | GB00BSZM1369 | ORD 20P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 990.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/1/2017 09:00 | In a way even the in line revenues were a positive, because in the interim statement in August, they did say that there could be am impact on revenue recognition but to the benefit of recurring revenues, so a change in there licence order model. Worth noting that license orders were very strong in last quarter. | interceptor2 | |
30/1/2017 08:46 | Excellent update!! I agree. One thing could better that they would exceed revenue Trinko | trinko | |
30/1/2017 08:40 | Trading update issued today At the time of the interim report issued in August 2016 we reported encouraging continued progress of the Company, and reiterated the positive shift in the momentum of the business that had started the previous year. We are very pleased to report that this continued to translate into a strong performance in the second half of 2016, driven by a large number of license orders in the final quarter, including substantial activity with major enterprise customers. In addition to the effect of the stronger sales performance, the profitability of the business was further enhanced by cost efficiencies over the course of the year, and to a lesser extent by foreign exchange gains linked to the sharp fall in Sterling. As a consequence, the Board expects that reported revenues for the year ended 31 December 2016 will be in line with current market expectations. The Board also expects that, even when excluding the impact of the positive foreign exchange effects, EBITDA will be ahead, and pre-tax profits significantly ahead, of current market expectations. Up 8% this morning. | vetpeter2 | |
30/1/2017 08:38 | What an excellent update, I really couldn't have hoped for anything better. Sopheon are the best type of investment that just keeps on giving :o)) | interceptor2 | |
30/1/2017 07:53 | Sounds pretty good! Well done Sopheon! "Substantial activity with major enterprise customers" "...significantly ahead" | samsj | |
30/1/2017 07:49 | Fantastic RNS. Well done everyone at Sopheon for all the hard work. I agree with cfro that its great to see the outcome wasn't reliant on fall of £. Hold tight for an interesting day ahead :-)) | eagle eye | |
30/1/2017 07:45 | Could go back on the dividend list. Profits significantly ahead...... | chadders | |
30/1/2017 07:42 | its up today i think | trinko | |
30/1/2017 07:41 | Thats the trading update we were all patiently waiting for....:-) Note the words used: even when excluding the impact of the positive foreign exchange effects... | cfro | |
30/1/2017 07:33 | rns issued this morning is on advfn | meganxmas | |
30/1/2017 07:11 | ......the Board expects that reported revenues for the year ended 31 December 2016 will be in line with current market expectations. The Board also expects that, even when excluding the impact of the positive foreign exchange effects, EBITDA will be ahead, and pre-tax profits significantly ahead, of current market expectations. The financial expectations noted above are subject to the completion of year-end financial close and audit processes. Sopheon intends to issue its results for the year ended 31 December 2016, on 23 March 2017. | janeann | |
24/1/2017 16:45 | Expecting an update in the morning based upon previous years -last Wed in Jan in 3 of last 4 years. Top sliced just before the close 336.75p but they remain one of my biggest holdings. Expecting recent progress to be maintained. GLA. | martinthebrave | |
20/1/2017 08:35 | trinko, looks a bit better. Apart from the potential turn, there has been no change to the basic chart set up. | bamboo2 | |
19/1/2017 12:13 | Maybe a rally later today if Sopheon is in here?? TODAY at 4:30pm sharp, my team’s latest small-cap ‘Buy’ recommendation and accompanying research report will be delivered straight to the inbox of an exclusive group of private investors – the members of my small-cap advisory service, Motley Fool Hidden Winners. Trinko | trinko | |
19/1/2017 10:07 | You where RIGHTT Bamboo | trinko | |
18/1/2017 15:42 | Thanks Bamboo! Can you post the chart? | trinko | |
18/1/2017 15:29 | My chart shows a triangle apex based potential turn tomorrow. We could do with it! lol | bamboo2 | |
16/1/2017 09:20 | Last year they released a trading update second week of January and in 2015 it was the last week. With 70% of revenue from the USA, I would think that the probability would favour momentum continuing from the last interim statement in August. | interceptor2 | |
16/1/2017 09:10 | There should be a trading update soon (January). | bruceylegs | |
13/1/2017 15:14 | Down to 345... what happened? Thought this was on my RNS feed, bad results, bad news? Did Trump tweet? | runthejoules | |
11/1/2017 15:54 | 1-11-2017 Best 10 Aim caps??? Name Mkt Cap (£m) QM Rank P/E Ratio Yield % Sector Brainjuicer 67.2 99 19.1 3.1 Consumer Cyclicals Boohoo.Com 1,612 99 80.4 - Consumer Cyclicals ULS Technology 58.5 99 18.8 2.4 Technology Beximco Pharmaceuticals 261.6 99 9.4 2 Healthcare Somero Enterprises 122.2 99 10.8 3.2 Industrials iomart 331.4 99 19.5 - Technology D4t4 Solutions 64.8 98 18.6 1.3 Technology Craneware 354.5 98 37.4 1.4 Healthcare Sopheon 26.9 98 17.8 - Technology Safestyle UK 256.9 98 15.8 3.7 Consumer Cyclicals | trinko |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions